International consensus on the use of tau PET imaging agent ${}^{18}$F-flortaucipir in Alzheimer's disease

Positron emission tomography (PET) with the first and only tau targeting radiotracer of ${}^{18}$F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform ${}^{18}$F-flortaucipir PET imaging. A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for ${}^{18}$F-flortaucipir PET imaging in Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. This international consensus and practice guideline will help to promote the standardized use of ${}^{18}$F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.